v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues        
Services $ 88,896 $ 68,434 $ 366,150 $ 155,713
Product 538,381 406,088 914,200 886,141
Total Revenues 627,277 474,522 1,280,350 1,041,854
Operating Expenses        
Research and development 2,285,907 3,473,782 7,613,228 11,819,106
General and administrative 2,483,793 1,815,863 7,667,909 6,353,647
Sales and marketing 958,567 1,053,584 2,919,400 4,112,731
Total Operating Expenses 5,728,267 6,343,229 18,200,537 22,285,484
Operating Loss (5,100,990) (5,868,707) (16,920,187) (21,243,630)
Other Income (Expenses)        
Grant income 232,184 85,378 429,411 85,378
Gain (Loss) on disposal of fixed assets 0 (1,195) 330 (34,693)
Interest income 160 530 478 9,634
Interest expense (143,800) (89,456) (363,825) (247,871)
Amortization of debt discount (729,630) 0 (1,054,935) 0
Gain on change in fair value of derivative liability 304,443 0 723,124 0
Gain (loss) on change in fair value of warrant liability 27,842 4,872 (14,884) 30,424
Total Other Income (Expenses) (308,801) 129 (280,301) (157,128)
Net Loss (5,409,791) (5,868,578) (17,200,488) (21,400,758)
Net Loss Attributable to Non-Controlling Interest (31,433) (47,049) (114,293) (226,295)
Net Loss Attributable to VolitionRx Limited Stockholders (5,378,358) (5,821,529) (17,086,195) (21,174,463)
Other Comprehensive Income (Loss)        
Foreign currency translation adjustments 22,348 (141,980) (807,577) (103,668)
Net Comprehensive Loss $ (5,387,443) $ (6,010,558) $ (18,008,065) $ (21,504,426)
Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited stockholders $ (0.05) $ (0.07) $ (0.17) $ (0.25)
Weighted Average Shares Outstanding        
- Basic and Diluted 108,213,068 87,886,012 102,115,278 84,165,579

Source

10-Q PDF
XBRL